Sugi Predict

Sugi Predict / Compounds / SCHEMBL2939101

SCHEMBL2939101

SCHEMBL2939101

CC(C)Cc1cnccc1CN1CC(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C1=O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.40
▸ TAS2R8 Q9NYW2 6/20 0.34
▸ PPARD Q03181 2/20 0.33
▸ PPARA Q07869 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CACNA1B Q00975 2/20 0.33
▸ ENPP2 Q13822 1/20 0.32
▸ PTGS2 P35354 2/20 0.32
▸ SCN9A Q15858 1/20 0.30
▸ CTSS P25774 1/20 0.30
▸ PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938324 0.90 IGF1R (0.42) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2937993 0.88 IGF1R (0.40) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2942706 0.88 IGF1R (0.41) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2931172 0.87 IGF1R (0.42) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2942410 0.86 IGF1R (0.42) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2935784 0.85 IGF1R (0.41) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2940350 0.85 IGF1R (0.41) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2939157 0.85 AOC1 (0.41) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL3727632 0.85 IGF1R (0.41) IGF1RTAS2R8PPARDPPARALMNA
SCHEMBL2938427 0.85 IGF1R (0.41) IGF1RTAS2R8PPARDPPARALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885TAS2R8 3914/4885PPARD 3189/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885TAS2R8 4047/4885PPARD 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.